Ciprofloxacin is a broad-spectrum fluoroquinolone antibiotic that has been a cornerstone in the treatment of various bacterial infections since its introduction in the 1980s. It exerts its bactericidal effect by inhibiting bacterial DNA gyrase and topoisomerase IV, enzymes critical for DNA replication, transcription, and repair. This action leads to the fragmentation of bacterial DNA and ultimately cell death. Ciprofloxacin is particularly effective against Gram-negative bacteria, including Enterobacteriaceae, Pseudomonas aeruginosa, and Neisseria species, and also has activity against some Gram-positive organisms such as Staphylococcus aureus, though its efficacy against Streptococcus pneumoniae and anaerobes is limited.
The drug is available in multiple formulations, including oral tablets, intravenous solutions, ophthalmic drops, and otic suspensions. Oral bioavailability is high, around 70-80%, and peak serum concentrations are reached within 1-2 hours. It is widely distributed into body tissues and fluids, including bone, prostate, and lung, making it useful for infections in these sites. Ciprofloxacin is metabolized in the liver and excreted primarily by the kidneys, requiring dose adjustment in patients with renal impairment.
Clinically, ciprofloxacin is indicated for a variety of infections. It is a first-line agent for Achat Acofide 100mg (http://electrolabexpress.com/) acute uncomplicated cystitis in women when other options are unsuitable, though its use is often reserved due to resistance and side effects. It is also used for complicated urinary tract infections, pyelonephritis, and prostatitis. Respiratory infections, particularly those caused by Gram-negative organisms such as Pseudomonas aeruginosa in cystic fibrosis patients, are another major indication. Additionally, ciprofloxacin is employed in gastrointestinal infections like traveler’s diarrhea, typhoid fever, and infectious diarrhea due to Campylobacter, Shigella, or E. coli. It is also a key drug for bone and joint infections, intra-abdominal infections, and certain sexually transmitted infections, though its role in gonorrhea has diminished due to rising resistance.
A particularly important use is as prophylaxis and treatment for anthrax, where ciprofloxacin is a drug of choice after inhalational exposure to Bacillus anthracis. It is also used in treating plague and tularemia, making it a critical agent for bioterrorism preparedness.
Despite its efficacy, ciprofloxacin is associated with significant adverse effects. The most common are gastrointestinal disturbances such as nausea, diarrhea, and vomiting. More serious but less frequent effects include tendonitis and tendon rupture, especially affecting the Achilles tendon, with risk increased in patients over 60, those on concomitant corticosteroids, and those with renal, heart, or lung transplants. This has led to a boxed warning from the US FDA. Other serious adverse effects include peripheral neuropathy, central nervous system effects like dizziness, confusion, and seizures, QTc interval prolongation predisposing to arrhythmias, and Clostridioides difficile colitis. Hypersensitivity reactions, including anaphylaxis and severe skin reactions like Stevens-Johnson syndrome, can also occur.
Ciprofloxacin is contraindicated in pregnant and breastfeeding women due to potential arthropathy in developing joints observed in animal studies, and in children except for specific serious infections where the benefits outweigh risks, such as in cystic fibrosis or anthrax. It should be used cautiously in patients with epilepsy, myasthenia gravis, or known QT prolongation.
Drug interactions are notable. Ciprofloxacin can increase the effect of oral anticoagulants like warfarin, requiring INR monitoring. It also raises theophylline and caffeine levels by inhibiting their metabolism, leading to toxicity. Co-administration with nonsteroidal anti-inflammatory drugs (NSAIDs) may increase CNS stimulation and seizure risk. Metal cations in antacids, sucralfate, iron, zinc, and dairy products significantly reduce ciprofloxacin absorption, so they should be taken at least 2 hours apart from the antibiotic.
Antimicrobial resistance is a growing concern. Fluoroquinolone resistance arises through chromosomal mutations in target enzymes, altered drug permeability, and efflux pumps. Overuse has led to high resistance rates in E. coli, Campylobacter, and Neisseria gonorrhoeae, limiting its empirical use. In some regions, resistance rates exceed 20%, prompting guidelines to recommend ciprofloxacin only when susceptibility is confirmed or for specific indications.
The Food and Drug Administration (FDA) has issued multiple safety warnings, restricting fluoroquinolone use for uncomplicated infections unless no other options exist. The European Medicines Agency also advises limiting use to conditions where the benefit outweighs the risk of disabling and potentially irreversible adverse reactions.
In summary, ciprofloxacin remains a potent antibiotic with a broad range of applications, particularly for Gram-negative infections and biodefense. However, its use must be tempered by careful consideration of adverse effects, drug interactions, and the threat of resistance. Prescribers should reserve ciprofloxacin for infections where alternative agents are not available or are contraindicated, and patients should be monitored closely for signs of tendinopathy or neurotoxicity. Proper stewardship and ongoing surveillance are essential to preserve the utility of this valuable antibiotic for future generations.